Specific type IV phosphodiesterase inhibitor ameliorates thioacetamide‐induced liver injury in rats
Specific type IV phosphodiesterase inhibitor ameliorates thioacetamide‐induced liver injury in rats
复制标题
DOI：
10.1111/j.1440-1746.2004.03512.x
复制
发表时间：
2005-01
影响因子：
4.1
通讯作者：
T. Matsuhashi;M. Otaka;M. Odashima;M. Jin;K. Komatsu;Noriaki Konishi;Isao Wada;Toshihiro Sato;Y. Horikawa;Reina Ohba;Jinko Oyaké;Natsumi Hatakeyama;Sumio Watanabe
中科院分区：
文献类型：
--
作者：
T. Matsuhashi;M. Otaka;M. Odashima;M. Jin;K. Komatsu;Noriaki Konishi;Isao Wada;Toshihiro Sato;Y. Horikawa;Reina Ohba;Jinko Oyaké;Natsumi Hatakeyama;Sumio Watanabe
背景和目的：罗利普兰是一种特异性的IV型磷酸二酯酶抑制剂，可抑制免疫细胞的活性和促炎细胞因子的产生。在本研究中，我们以硫代乙酰胺(TAA)诱导的大鼠急性肝损伤为模型，评价了罗利普兰对急性肝损伤的影响。
Background and Aims: Rolipram is a specific type IV phosphodiesterase inhibitor that suppresses the activity of immune cells and the production of pro‐inflammatory cytokines. In this study, we assessed the effect of rolipram on acute liver injury using thioacetamide (TAA)‐induced liver injury in rats as a model.